申请人:Les Laboratoires Servier
公开号:US06350757B1
公开(公告)日:2002-02-26
A compound selected from those of formula (I):
wherein:
represents single or double bond,
R1 represents hydrogen, alkyl, —R6-aryl, —R6-cycloalkyl, —R6-heterocycle, —CO2R7—, —COR8, or —CONHR8, wherein R6, R7, and R8 are as defined in the description,
R2 represents cyano, mono- or di-alkylaminoalkylaminocarbonyl, —CO2R8, —CONHR8, —NR8R9, —NHCO2R7, or —COR8 wherein R7, R8, and R9 are as defined in the description,
R3 and R4 together form (C3-C10)cycloalkyl,
R5 represents hydrogen, alkyl, or arylalkyl,
Ra, Rb, Rc, Rd, which may be identical or different, represent a group as defined in the description,
its isomers, and pharmaceutically-acceptable acid or base addition salts thereof, and medicinal products containing the same which are useful in the treatment of CNS disorders.
从以下公式(I)中选择的化合物:其中:表示单键或双键,R1表示氢、烷基、—R6-芳基、—R6-环烷基、—R6-杂环烷基、—CO2R7—、—COR8或—CONHR8,其中R6、R7和R8如描述中定义,R2表示氰基、单烷基或二烷基氨基甲酰基、—CO2R8、—CONHR8、—NR8R9、—NHCO2R7或—COR8,其中R7、R8和R9如描述中定义,R3和R4共同形成(C3-C10)环烷基,R5表示氢、烷基或芳基烷基,Ra、Rb、Rc、Rd,可以相同也可以不同,表示如描述中定义的基团,其异构体和药学上可接受的酸盐或碱盐,以及含有这些化合物的治疗中枢神经系统疾病的药物产品。